Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
NCT05424731 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-01-15
Summary
This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.
Conditions
Interventions
- COMBINATION_PRODUCT
-
DBV712 250 mcg
Daily epicutaneous delivery.
Sponsors & Collaborators
-
DBV Technologies
lead INDUSTRY
Eligibility
- Min Age
- 2 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
NCT07349212 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Epicutaneous Immunotherapy in Peanut Allergy in Children
NCT01197053 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
NCT02402231 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
NCT03793608 ·Status: COMPLETED ·Phase: PHASE2
-
Salvage Peanut Oral Immunotherapy Study
NCT03251508 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
STEP-IT-UP - Peanut Allergy Study for Infants
NCT04761835 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects
NCT03070561 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
NCT00382148 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Immunotherapy (OIT) for Peanut Allergy
NCT00815035 ·Status: COMPLETED ·Phase: PHASE2
-
Peanut Oral Immunotherapy in Children
NCT01867671 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Peanut Immunotherapy
NCT01324401 ·Status: COMPLETED ·Phase: NA
-
Xolair Enhances Oral Desensitization in Peanut Allergic Patients
NCT01290913 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)
NCT04037176 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
NCT04974970 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy
NCT01897077 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
NCT00932282 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
NCT01084174 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Omalizumab in the Treatment of Peanut Allergy
NCT00949078 ·Status: COMPLETED ·Phase: PHASE2
-
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
NCT05138757 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
NCT03682770 ·Status: COMPLETED ·Phase: PHASE2
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
NCT01781637 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Oral Immunotherapy for Peanut Allergy (PMIT)
NCT00597675 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Xolair in Peanut Allergy
NCT00086606 ·Status: TERMINATED ·Phase: PHASE2
-
Oral Peanut Immunotherapy for Peanut Allergic Patients
NCT01891136 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
NCT03881696 ·Status: COMPLETED ·Phase: PHASE3